ALLMedicine™ Diarrhea Center

Dec 4th, 2021 - High-dose melphalan is an integral part of conditioning chemotherapy prior to both autologous and allogeneic hematopoietic cell transplantation. While underexposure may lead to relapse, overexposure may lead to toxicities include mucositis, diarrh...

Dec 4th, 2021 - Rotavirus is the most common cause of severe diarrhea among children worldwide. In 2017, Italy included rotavirus vaccination in its National Immunization Program. The use of social media monitoring, an efficient tool to understand vaccine hesitan...

Dec 3rd, 2021 - This is a phase IIa, randomized, placebo-controlled, single-blinded superiority treatment study in males and non-pregnant females, 18 to 65 years of age who are in good health. This study is designed to compare placebo to once daily doses of 6mg a...

Dec 3rd, 2021 - The main idea of the intervention is to conduct quarterly provider knowledge assessments at health facilities and to pay facilities a bonus if providers perform well on these tests. For the intervention, 12 clinical vignettes were created. These v...

Dec 3rd, 2021 - Potential etiological mechanisms of irritable bowel syndrome (IBS) have been reported, and emerging data suggest that immune activation is present in a major subset of IBS, especially in those with diarrhea. Intestinal mucosal mast cell and intrae...

May 19th, 2021 - Clostridioides difficile infection occurs when the bacterium produces toxin that causes diarrhea and inflammation of the colon. These guidelines indicate the preferred approach to the management of adults with C. difficile infection and represent ...

Jul 18th, 2020 - Thanks to ready access to hydrogen breath testing, small intestinal bacterial overgrowth is now commonly diagnosed among individuals presenting with a variety of gastrointestinal and even non-gastrointestinal complaints and is increasingly implica...

Mar 7th, 2020 - The NCCN Guidelines for Management of Immunotherapy-Related Toxicities provide interdisciplinary guidance on the management of immune-related adverse events (irAEs) resulting from cancer immunotherapy. These NCCN Guidelines Insights describe sympt...

Oct 2nd, 2019 - Acute noninfectious diarrhea is a common phenomenon in intensive care unit patients. Multiple treatments are suggested but the most effective management is unknown. A working group of the Eastern Association for the Surgery of Trauma, aimed to eva...

Sep 19th, 2019 - Chronic diarrhea affects about 5% of the population overall. Altered bile acid metabolism is a common but frequently undiagnosed cause. We performed a systematic search of publication databases for studies of assessment and management of bile acid...

Dec 3rd, 2021 - This is a phase IIa, randomized, placebo-controlled, single-blinded superiority treatment study in males and non-pregnant females, 18 to 65 years of age who are in good health. This study is designed to compare placebo to once daily doses of 6mg a...

Dec 3rd, 2021 - The main idea of the intervention is to conduct quarterly provider knowledge assessments at health facilities and to pay facilities a bonus if providers perform well on these tests. For the intervention, 12 clinical vignettes were created. These v...

Nov 29th, 2021 - Currently, pneumonia diagnosis is primarily based on clinical symptoms such as cough, shortness of breath, chest pain, fever and sputum production, combined with X-ray of the lungs, relevant blood tests and microbiological analysis of sputum sampl...

Nov 24th, 2021 - The objective of this Endpoint Determination Study is to address key elements regarding a proposed larger clinical study design: Comparing different potential primary outcome measures Demonstrating that an exclusionary diet as determined by elevat...

Nov 23rd, 2021 - Primary dysmenorrhea is defined as cramping pain in the lower abdomen that occurs before or during menstruation without identifiable pelvic pathology. Secondary symptoms include nausea, vomiting, fatigue, back pain, headaches, dizziness, and diarr...

Dec 1st, 2021 - The addition of BO-112 to pembrolizumab (Keytruda) produced clinical benefit in patients with unresectable malignant melanoma who have experienced disease progression on anti–PD-1 therapy, according to data from the preliminary analysis of the pha...

Dec 1st, 2021 - Retifanlimab (INCMGA 0012) demonstrated encouraging antitumor activity with favorable tolerability in patients with recurrent microsatellite instability–high (MSI-H) or mismatch repair deficient (dMMR) endometrial cancer, according to data from th...

Nov 29th, 2021 - The European Commission has approved the combination of pembrolizumab (Keytruda) and lenvatinib (Lenvima) for the treatment of patients with advanced renal cell carcinoma (RCC).1 The decision is based on findings from the phase 3 CLEAR (Study 307...

Nov 23rd, 2021 - Iván Márquez Rodas, MD, PhD, coordinator, Heredofamilial Cancer Unit, Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense, Madrid, Spain, discusses the preliminary results of the phase 2 SPOTLIGHT203 trial (NCT04570332),...

Nov 23rd, 2021 - The combination of enasidenib (Idhifa) plus azacitidine (Onureg) was well tolerated and induced significantly improved response rates compared with azacitidine alone in patients with newly diagnosed, IDH2-mutant acute myeloid leukemia (AML), accor...